Clinical Trials Browser

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

NCT06796907 2025-10-14

BEHOLD-2

Phase 1/2 Recruiting

392 enrolled

Tumor-Agnostic

Neoplasms

NCT04926324 2025-06-29

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

Phase 1/2 Terminated

3 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06385548 2025-04-01

LiDer

Phase 1/2 Withdrawn

Gynecologic

Endometrial Neoplasms

NCT05784012 2025-03-13

RADIAN

Phase 1/2 Recruiting

34 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Phase 1/2 Terminated

4 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT05060432 2024-06-21

TIG-006

Phase 1/2 Active not recruiting

153 enrolled

DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

Clinical Trials

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

PULMO-01

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer